Merch
Medical card
A busy week across the United States saw the federal marijuana rescheduling process hit another procedural delay, while several states advanced notable legislative and regulatory actions. In Europe, the UK medical cannabis supply chain continued to expand and the Netherlands’ pioneering Bedrocan faced a financial crisis.
United States
DEA Judge Pauses Rescheduling Hearing After Watchdog Report
The long-running DEA administrative hearing on the Trump administration’s proposal to move cannabis from Schedule I to Schedule III hit a fresh obstacle this week. Chief Administrative Law Judge Derek Julius granted a request from rescheduling opponents to pause proceedings after a federal watchdog issued a report identifying “gaps” in the federal review processes underpinning the proposal. The judge has asked agency officials and other participants to weigh in before the hearing resumes. The development extends a process that has already stretched across multiple years and adds further uncertainty about when, or whether, a final recommendation will reach the DEA administrator.
The Cannigma’s Take: The irony is that the watchdog report being used to slow rescheduling found DEA agreed with HHS in every one of the 84 recent scheduling cases that reached a final rule. Its criticism is really about undocumented procedures, not evidence that the government’s cannabis science was unsound
GOP Senators Call for DOJ Investigation Into Chinese Criminal Networks in Cannabis
A group of Republican senators led by Sen. Tom Cotton (R-AR) sent a letter to Attorney General Todd Blanche this week urging the Justice Department to investigate what they describe as the “growing role of Chinese transnational criminal organizations” in U.S. marijuana and hemp markets. The senators specifically invoked the federal hemp loophole, arguing that intoxicating hemp products have created an opening that criminal networks are exploiting. The move adds a national security dimension to the ongoing federal debate over hemp regulation and could increase pressure on the DOJ to act ahead of any new Farm Bill framework.
The Cannigma’s Take: Congress is already poised to strip many intoxicating products of federal hemp status, but that would do little by itself about the senators’ other allegations involving illegal grows, land acquisition and trafficked workers. Closing the “hemp loophole” and dismantling organised criminal networks are related political narratives, but very different enforcement jobs.
Florida Activists File Two New Legalization Ballot Measures
Two separate groups submitted proposed recreational marijuana legalization ballot initiatives to Florida state officials this week. The first, from Floridians for Marijuana, would permit adults 21 and older to possess up to two ounces of cannabis. A second measure was also filed, giving activists an early start on the signature-gathering process required to reach the 2028 ballot. Florida voters narrowly rejected a legalization measure in November 2024, falling short of the 60 percent supermajority threshold required for constitutional amendments, making these new filings the next attempt to revisit the question.
The Cannigma’s Take: Florida’s next cannabis campaign has a procedural uphill battle that the 2024 effort did not face in quite the same form. The state has since tightened petition circulation rules (including registration requirements for anyone handling more than 25 signed petitions) while passage still requires 60% of the vote, making ballot access itself an increasingly important part of the legalisation fight.
Massachusetts Legalization Repeal Faces Uphill Battle, Polls and New Ads Show
As reported in some our recent weekly roundups, Massachusetts voters will decide in November on a ballot measure that would roll back the state’s recreational marijuana law. A new poll from CommonWealth Beacon and MassINC found a sizable majority of voters oppose the rollback, consistent with earlier surveys. The “No on 8” campaign this week launched two new television ads urging voters to reject the measure. The polling and advertising activity signal that opponents of repeal are treating the race seriously despite their apparent polling advantage.
The Cannigma’s Take: As we’ve mentioned before, Question 8 is not really a return to prohibition – it would preserve limited adult possession and gifting while eliminating the lawful recreational supply chain. That combination, of course, risks creating something stranger: legally tolerated demand supplied largely through an illicit or grey market.
California Governor Signs Multiple Cannabis Bills
California Governor Gavin Newsom signed several cannabis-related bills into law this week. AB 2532 introduces new packaging and labeling requirements for THC-infused edibles and beverages, including a requirement to display a poison control hotline number. Separately, Newsom approved AB 1965 and a companion measure revising rules on product testing, seed-to-sale tracking, and consumer access to cannabinoid content information. The bills represent incremental tightening of California’s regulatory framework rather than structural changes to the market.
The Cannigma’s Take: California lawmakers originally considered limiting cannabis beverages to 10mg THC per container, then stripped that provision out. The final approach therefore manages dosing risk through serving information, measurement and warnings rather than restricting product strength… a meaningful bet on consumer behaviour over product prohibition.
Maryland Extends Workplace Protections and Veterinary Allowances
Two new Maryland laws took effect this week. One protects firefighters and rescue workers from employment penalties for lawful off-duty medical marijuana use, following Governor Wes Moore’s signature in April. A second law shields veterinarians from professional discipline by the State Board of Veterinary Medical Examiners for recommending medical cannabis to animal patients. Both measures had been signed earlier in the year and came into force on October 1.
The Cannigma’s Take: Maryland is drawing a distinction that safety-sensitive employers have often resisted: lawful cannabis use is not synonymous with workplace impairment. The firefighter law protects medical use while separately requiring employers to report employees who actually arrive impaired, a potentially important model for moving cannabis employment policy away from status-based punishment.
Pennsylvania: Competing Signals on Legalization and Hemp
Pennsylvania produced conflicting signals this week. The state’s top Republican senator said he does not expect recreational legalization to advance this year and believes the state should wait for federal direction before acting, even as the Democratic-controlled House speaker has suggested legalization could move in 2026. On a separate track, a Republican state senator announced plans to introduce the Pennsylvania Hemp and Cannabinoid Act, which would keep hemp THC products legal while adding age limits, registration, testing, and labeling requirements. A Senate committee also unanimously advanced a bill that would allow terminally ill patients to use medical cannabis in hospitals.
The Cannigma’s Take: Pennsylvania Republicans are invoking federal uncertainty in opposite ways: Senate leader Joe Pittman says it is a reason to wait on marijuana legalisation, while Sen. Dawn Keefer says Pennsylvania “cannot wait” for Washington before regulating hemp cannabinoids. Something’s got to give!
Georgia Approves Medical Marijuana Delivery, Including Possible USPS Route
Georgia regulators approved new rules this week permitting medical marijuana to be delivered directly to patients through the U.S. Postal Service and private carriers such as FedEx, UPS, and DHL. However, none of those carriers has confirmed they will participate, and USPS declined to say whether it would take part given that cannabis remains a federally controlled substance. The rules create a legal framework for delivery but leave the practical question of carrier participation unresolved.
The Cannigma’s Take: Georgia can authorise cannabis delivery, but it cannot make federally unlawful cannabis mailable. USPS rules say mailing a controlled substance is unlawful where its distribution violates the Controlled Substances Act, so the postal provision is largely future-proofing unless federal law or a specific federal authorisation changes.
New York Recreational Market Surpasses $4 Billion in Sales
New York’s Office of Cannabis Management announced at a Cannabis Control Board meeting this week that the state’s adult-use dispensaries have now recorded more than $4.1 billion in total recreational sales since the market launched. The milestone reflects the continued growth of a market that had a slow and legally complicated start but has expanded significantly as more licensed dispensaries have opened.
The Cannigma’s Take: New York can now point simultaneously to enormous market scale and a majority of adult-use licences going to social and economic equity applicants. But licence distribution is only the first test of equity: a multibillion-dollar market makes the more important question whether those businesses are capturing durable revenue, capital and market share rather than simply licences.
Europe and UK
Bedrocan Applies for Court-Supervised Insolvency Protection in the Netherlands
Bedrocan, the Dutch company that has supplied government-approved medical cannabis in the Netherlands for decades and is relied upon by thousands of patients, applied this week for a court-supervised suspension of payments for its two Dutch entities. The move, known in Dutch law as “surseance van betaling,” is a formal insolvency protection mechanism intended to give the company time to restructure. The financial difficulties of one of Europe’s oldest and most established medical cannabis producers highlight the commercial pressures facing even well-entrenched operators in the sector.
The Cannigma’s Take: Bedrocan’s crisis looks less like a conventional cannabis-company bust than a failure of regulatory sequencing. The Dutch state ended a 23-year supply relationship while the replacement rules that were supposed to let Bedrocan operate more directly in the market remained delayed… effectively dismantling the old bridge before completing the new one
UK Medical Cannabis Supply Chain Expands With Two New Deals
Two supply-side developments strengthened the UK medical cannabis market this week. Curaleaf Laboratories and Vericura announced a distribution agreement aimed at expanding manufacturing and supply of medical cannabis products across the UK, combining Curaleaf’s pharmaceutical production capacity with Vericura’s specialist distribution network. Separately, Irish manufacturer Dunbar Pharmaceuticals launched what it describes as the UK’s first plant-derived dronabinol oral spray, manufactured at an MHRA-licensed facility in Surrey, extending a pharma-grade THC product line that had previously been available only in capsule form.
The Cannigma’s Take: The UK supply chain is becoming increasingly sophisticated without the underlying medicines necessarily becoming licensed products. Much of this infrastructure still serves the MHRA’s “specials” route (individually prescribed unlicensed medicines) meaning commercial and manufacturing maturity is running well ahead of conventional drug approval.
Spain’s Cannabis Status Remains a Legal Grey Area
A detailed assessment published this week confirmed that Spain’s cannabis framework remains one of Europe’s most ambiguous. Private possession and consumption are not covered by the Penal Code through a judicial interpretation gap rather than formal decriminalisation, while public possession is a fineable administrative offence. Cannabis social clubs operate in a legal grey zone, with their status varying by region and subject to ongoing court challenges. No national legislative reform is currently moving through parliament, leaving the market in a prolonged state of regulatory uncertainty.
The Cannigma’s Take: Spain’s ambiguity is partly structural and not just legislative inertia. Its courts have repeatedly blocked regional and municipal attempts to regularise cannabis clubs because criminal drug policy belongs to the national state. That leaves clubs in a peculiar trap where they are tolerated enough to persist, yet unable to obtain durable legality from the governments closest to them.
Rest of World
Global Regulatory Summit Publishes Blueprint for International Alignment
The Global Cannabis Regulatory Summit published a 100-page white paper this week setting out a framework for harmonising cannabis regulation across jurisdictions. The document diagnoses a fragmented global regulatory landscape and proposes a working architecture for alignment, noting that while a legal framework for medical cannabis has existed for more than 60 years, coherent cross-border regulatory standards have not followed. The paper is aimed at policymakers and regulators across multiple regions and is intended to inform ongoing national and international reform discussions.
The Cannigma’s Take: There is a caution to be aware of here. The summit includes regulators and standards bodies, but major cannabis companies are also – of course – prominent financial and institutional partners. That need not invalidate the work, but if voluntary standards become de facto conditions for global market access, governments will need to ensure the rulebook is not effectively written by the firms best equipped to comply with it. Stop me if you’ve heard this one before?
Contradictions and Tensions
More on the federal rescheduling process and state-level momentum. The DEA judge’s decision to pause the rescheduling hearing, prompted by a watchdog report on procedural gaps, further delays a process that states, regulators, and industry operators have been waiting on for years. Yet states, as we keep reporting, are not waiting: California is tightening its regulatory framework, Georgia is opening delivery channels, and New York is reporting multi-billion-dollar market milestones, all under a federal Schedule I classification that the pause leaves intact for longer. Pennsylvania’s top Republican senator explicitly said states should wait for federal direction before legalising, which puts him at odds with the Democratic House speaker’s timeline and with the broader pattern of states acting regardless of Washington.
The GOP senators’ call for a DOJ investigation into Chinese criminal networks in cannabis also sits in tension with the rescheduling delay. Senators are pressing for aggressive federal enforcement in the cannabis space at the same moment that the federal rescheduling process, which would bring cannabis under a more coherent regulatory structure, is being slowed by procedural objections from some of the same ideological quarter. Tighter federal regulation through rescheduling could address some of the illicit market concerns the senators raise, yet the effect of the watchdog-driven pause is to keep the current fragmented framework in place longer.
Sign up for bi-weekly updates, packed full of cannabis education, recipes, and tips. Your inbox will love it.
